𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Symptomatic effect of selegiline in de novo parkinsonian patients

✍ Scribed by Prof. H. Allain; P. Pollak; H. C. Neukirch


Book ID
102504390
Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
408 KB
Volume
8
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Selegiline in de novo parkinsonian patie
✍ Prof. V. V. MyllylΓ€; K. A. Sotaniemi; J. A. Vuorinen; E. H. Heinonen πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 353 KB

Selegiline (L-deprenyl) has been recommended as an antiparkinsonian drug to be used as an adjunct to therapy with L-dopa, if and when L-dopa starts to lose its effect. However, initial selegiline monotherapy followed by L-dopa may be both effective and safe. A double-blind, placebo-controlled trial